Ident. | Authors (with country if any) | Title |
---|
000006 (2013) |
Connie Marras [Canada] ; Anthony Lang [Canada] | Parkinson's disease subtypes: lost in translation? |
000046 (2011) |
Pascal Van [Canada] ; Catriona Steele [Canada] ; Anthony Lang [Canada] | Tongue control for swallowing in Parkinson's disease: Effects of age, rate, and stimulus consistency |
000059 (2011) |
Kazutaka Kobayashi [États-Unis, Japon] ; Anthony Lang [Canada] ; Mark Hallett [États-Unis] ; Frederick Lenz [États-Unis] | Thalamic neuronal and EMG activity in psychogenic dystonia compared with organic dystonia |
000106 (2011) |
Connie Marras [Canada] ; Michael Mcdermott [États-Unis] ; Ken Marek [États-Unis] ; Paula Rochon [Canada] ; Gary Naglie [Canada] ; Caroline Tanner [États-Unis] ; Alice Rudolph [États-Unis] ; Ira Shoulson [États-Unis] ; Anthony Lang [Canada] | Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts |
000122 (2011) |
Cristina Sampaio [Portugal] ; Juliana Bronzova [Pays-Bas] ; Robert Hauser [États-Unis] ; Anthony Lang [Canada] ; Olivier Rascol [France] ; Serge Van [Pays-Bas] ; And Theeuwes [Pays-Bas] | Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials |
000250 (2011) |
Robert Altman [Canada] ; Anthony Lang [Canada] ; Ronald Postuma [Canada] | Caffeine in Parkinson's disease: A pilot open‐label, dose‐escalation study |
000318 (2010) |
Shen Lim [Canada, Malaisie] ; Anthony Lang [Canada] | The nonmotor symptoms of Parkinson's disease—An overview |
000321 (2010) |
Tiago Mestre [Portugal] ; Anthony Lang [Canada] | The grasp reflex: A symptom in need of treatment |
000354 (2010) |
Michael Okun [États-Unis] ; Anthony Lang [Canada] ; Joseph Jankovic [États-Unis] | Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease |
000420 (2010) |
Elena Moro [Canada] ; Andres Lozano [Canada] ; Pierre Pollak [France] ; Yves Agid [France] ; Stig Rehncrona [Suède] ; Jens Volkmann [Allemagne] ; Jaime Kulisevsky [Espagne] ; Jose Obeso [Espagne] ; Alberto Albanese [Italie] ; Marwan Hariz [Royaume-Uni, Suède] ; Niall Quinn [Royaume-Uni] ; Jans Speelman [Pays-Bas] ; Alim Benabid [France] ; Valerie Fraix [France] ; Alexandre Mendes [France] ; Marie Welter [France] ; Jean Houeto [France] ; Philippe Cornu [France] ; Didier Dormont [France] ; Annalena Tornqvist [Suède] ; Ron Ekberg [Suède] ; Alfons Schnitzler [Allemagne] ; Lars Timmermann [Allemagne] ; Lars Wojtecki [Allemagne] ; Andres Gironell [Espagne] ; Maria Rodriguez [Espagne] ; Jorge Guridi [Espagne] ; Anna Bentivoglio [Italie] ; Maria Contarino [Italie, Pays-Bas] ; Luigi Romito [Italie] ; Massimo Scerrati [Italie] ; Marc Janssens [Pays-Bas] ; Anthony Lang [Canada] | Long‐term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease |
000423 (2010) |
Galit Kleiner [Canada] ; Andres Lozano [Canada] ; Elena Moro [Canada] ; Yu Poon [Canada] ; Anthony Lang [Canada] | Long‐term effect of unilateral pallidotomy on levodopa‐induced dyskinesia |
000432 (2010) |
Zhen Ni [Canada] ; Andrew Pinto [Canada] ; Anthony Lang [Canada] ; Robert Chen [Canada] | Involvement of the cerebellothalamocortical pathway in Parkinson disease |
000433 (2010) |
Fabrizio Stocchi [Italie] ; Olivier Rascol [France] ; Karl Kieburtz [États-Unis] ; Werner Poewe [Autriche] ; Joseph Jankovic [États-Unis] ; Eduardo Tolosa [Espagne] ; Paulo Barone [Italie] ; Anthony Lang [Canada] ; C Olanow [Italie, États-Unis] | Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study |
000477 (2010) |
Fabrizio Stocchi ; Olivier Rascol [France] ; Karl Kieburtz ; Werner Poewe ; Joseph Jankovic [États-Unis] ; Eduardo Tolosa ; Paulo Barone ; Anthony Lang ; C Olanow | Erratum: Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study |
000490 (2010) |
Amitabh Gupta [Canada] ; Anthony Lang [Canada] | Drug‐induced cranial myoclonus |
000492 (2010) |
Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert Hauser [États-Unis] ; Anthony Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge Van [Pays-Bas] ; Guus Van [Pays-Bas] | Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease |
000521 (2010) |
Susanne Schneider [Royaume-Uni, Allemagne] ; Anthony Lang [Canada] ; Elena Moro [Canada] ; Benedikt Bader [Allemagne] ; Adrian Danek [Allemagne] ; Kailash Bhatia [Royaume-Uni] | Characteristic head drops and axial extension in advanced chorea‐acanthocytosis |
000524 (2010) |
Steven Schwid [États-Unis] ; Janice Bausch [États-Unis] ; David Oakes [États-Unis] ; Lynn Schuchter [États-Unis] ; Caroline Tanner [États-Unis] ; Misser Forrest [Danemark] ; Anthony Lang [Canada] ; Ira Shoulson [États-Unis] | Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease |
000561 (2010) |
Anette Schrag [Royaume-Uni] ; Shamira Sheikh [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Andrew Lees [Royaume-Uni] ; Caroline Selai [Royaume-Uni] ; Chris Mathias [Royaume-Uni] ; Irene Litvan [États-Unis] ; Anthony Lang [Canada] ; James Bower [États-Unis] ; David Burn [Royaume-Uni] ; Philip Low [États-Unis] ; Marjan Jahanshahi [Royaume-Uni] | A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy |
000737 (2009) |
Christine Klein [Allemagne, Canada] ; Susanne Schneider [Allemagne, Royaume-Uni] ; Anthony Lang [Canada] | Hereditary parkinsonism: Parkinson disease look‐alikes—An algorithm for clinicians to “PARK” genes and beyond |
000821 (2009) |
Bernard Ravina [États-Unis] ; Caroline Tanner [États-Unis] ; Diane Dieuliis [États-Unis] ; Shirley Eberly [États-Unis] ; Emily Flagg [États-Unis] ; Wendy Galpern [États-Unis] ; Stanley Fahn [États-Unis] ; Christopher Goetz [États-Unis] ; Stephen Grate [États-Unis] ; Roger Kurlan [États-Unis] ; Anthony Lang [Canada] ; Kenneth Marek [États-Unis] ; Karl Kieburtz [États-Unis] ; David Oakes [États-Unis] ; Robin Elliott [États-Unis] ; Ira Shoulson [États-Unis] | A longitudinal program for biomarker development in Parkinson's disease: A feasibility study |